Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Below Two Hundred Day Moving Average of $4.64

Capricor Therapeutics Inc (NASDAQ:CAPR) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.64 and traded as low as $2.95. Capricor Therapeutics shares last traded at $3.21, with a volume of 248,731 shares traded.

Analyst Ratings Changes

A number of research firms have issued reports on CAPR. HC Wainwright lifted their price target on Capricor Therapeutics from $18.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 4th. StockNews.com began coverage on Capricor Therapeutics in a report on Thursday, October 5th. They issued a “sell” rating on the stock.

Capricor Therapeutics Stock Performance

The company’s 50 day moving average price is $3.81 and its 200-day moving average price is $4.62. The stock has a market cap of $78.36 million, a P/E ratio of -2.64 and a beta of 4.06.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP boosted its stake in shares of Capricor Therapeutics by 144.9% in the 3rd quarter. GSA Capital Partners LLP now owns 43,805 shares of the biotechnology company’s stock worth $150,000 after buying an additional 25,915 shares during the last quarter. Citigroup Inc. bought a new stake in Capricor Therapeutics during the third quarter worth $211,000. Tower Research Capital LLC TRC boosted its position in Capricor Therapeutics by 39.5% in the second quarter. Tower Research Capital LLC TRC now owns 12,236 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 3,466 shares during the last quarter. Renaissance Technologies LLC grew its stake in Capricor Therapeutics by 52.1% in the 2nd quarter. Renaissance Technologies LLC now owns 46,421 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 15,900 shares during the period. Finally, BlackRock Inc. increased its position in shares of Capricor Therapeutics by 4.3% during the 2nd quarter. BlackRock Inc. now owns 410,921 shares of the biotechnology company’s stock valued at $1,964,000 after purchasing an additional 16,941 shares during the last quarter. 10.18% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.